Aclaris Therapeutics announced positive proof-of-concept results from its Phase 1b trials of ATI-052, a bispecific antibody targeting TSLP and IL-4Rα, in patients with severe atopic dermatitis (AD) and asthma. The company also disclosed a preliminary third quarter 2026 cash position to support its prioritized development of the candidate in eosinophilic esophagitis.
Key Highlights
- Patients with severe atopic dermatitis experienced a 45% placebo-adjusted mean improvement in EASI scores at day 57 following five weekly doses.
- A single 480 mg dose in asthma patients resulted in a 59% mean absolute reduction in FeNO (45 ppb) and a 200 mL placebo-adjusted improvement in FEV1 at day 15.
- Preliminary cash, cash equivalents, and marketable securities totaled $204.6 million as of September 30, 2026.